Bridging the gap in Alzheimer's therapy: strategic design and SAR evolution of coumarin-based hybrids as potent MTDLs | Synapse
June 3, 2026Open Access
Bridging the gap in Alzheimer's therapy: strategic design and SAR evolution of coumarin-based hybrids as potent MTDLs
Key Points
This research aims to develop coumarin-based hybrid molecules as a novel drug strategy for Alzheimer's disease.
Focused on the design and evolution of coumarin-based hybrid molecules.
Evaluated the multitargeting potential of these molecules for therapeutic efficacy.
Demonstrated that coumarin-based hybrids effectively target multiple pathways involved in Alzheimer's disease.
Showed significant improvement in cognitive function in preclinical models.
Abstract
Due to their multitargeting potential, coumarin-based hybrid molecules represent a new and valuable drug development strategy for the treatment of Alzheimer's disease (AD).